Clinical trials: Pervasive Development Disorders
Autism Spectrum Disorder
Efficacy and Safety of Slenyto for Insomnia in Children With ASD
This is a randomized placebo controlled study in children diagnosed with autism spectrum disorder (ASD), to Investigate the Efficacy and Safety of Slenyto® to alleviate Sleep Disturbances in these children. .
- Trial name
- ASD (NCT04233502)
- Testing
- Melatonin
- Sponsor
- Neurim Pharmaceuticals Ltd.
Autism Spectrum Disorder
Efficacy and Safety of Functional Neurogenesis Stimulation Therapy in Children With Autism Spectrum Disorder (ASD)
This study will test whether a noninvasive brain stimulation treatment called Functional Neurogenesis Stimulation (using the NeuroCytontron device) can safely improve core symptoms of Autism Spectrum Disorder (ASD) in children.
- Trial name
- NCT07276555
- Testing
- Functional Neurogenesis Stimulation Therapy
- Where
- 2 sites in United States, Mexico
- Volunteers
- 256 people
- Sponsor
- Neurocytonix, Inc.
Autism, Pediatric Autism
Open-label Study of Safety and Tolerability of Memantine in Children With Autism
The purpose of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of autism in pediatric patients.
- Trial name
- NCT01999894
- Testing
- Memantine HCl
- Where
- 19 sites in United States
- Volunteers
- 102 people
- Sponsor
- Forest Laboratories
Fragile X Syndrome, Autism
Effects of CX516 on Functioning in Fragile X Syndrome and Autism
This study will investigate whether CX516 can improve attention, memory, language, or behavior in adults with Fragile X Syndrome and/or Autism. CX516 is an AMPAKINE® compound. AMPAKINE compounds enhance synaptic strength.
- Trial name
- NCT00054730
- Testing
- CX516 (Ampalex®)
- Where
- 2 sites in United States
- Sponsor
- RespireRx
Social Anxiety in Autistic Adults
Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing social anxiety in adults with autism.
- Trial name
- NCT02008396
- Testing
- Midomafetamine HCl, Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Resilient Pharmaceuticals
15q Duplication Syndrome, CDKL5 Deficiency Disease
A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
The purpose of this study is to investigate the effect of soticlestat on the frequency of motor seizures for participants with Dup15q or CDD during the Maintenance Period.
- Trial name
- NCT03694275
- Testing
- Soticlestat
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Takeda
Autism Spectrum Disorder
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and adult subjects with ASD.
- Trial name
- NCT05081245
- Testing
- ML-004 (IR)/(ER) tablet
- Where
- 29 sites in United States, Australia and 1 more
- Volunteers
- 168 people
- Sponsor
- MapLight Therapeutics
Autism Spectrum Disorder (ASD)
Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD
This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.
- Trial name
- NCT06757504
- Testing
- TTYP01 Tablets (12mg or 18mg)
- Where
- 5 sites in China
- Volunteers
- 150 people
- Sponsor
- Shanghai Auzone Biological Technology Co., Ltd.
Autism Spectrum Disorder
Characterization of a Clinical Subpopulation in Children With Autism Spectrum Disorder
This single-center, observational study is being conducted to identify a well-characterized subgroup within the ASD patient population, based on clinical symptoms and biosample analysis.
- Trial name
- NCT04600882
- Where
- United States
- Sponsor
- Stalicla SA
Autism Spectrum Disorder
Brain Hero® Neurofeedback Training (With the Device Brainhero 2019, Type 201)
The study investigates the feasibility and the effects of training at home with personalised neurofeedback in children with an autism spectrum diagnosis and comorbidities.
- Trial name
- NCT05444816
- Testing
- Personalised Neurofeedback training at home
- Where
- 2 sites in Austria
- Volunteers
- 21 people
- Sponsor
- Brainhero GmbH
Autism Spectrum Disorder (ASD
Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, therapeutic exploratory Phase 2 clinical trial designed to evaluate the efficacy and safety of NV01-A02 in pediatric participants diagnosed with Autism Spectrum…
- Trial name
- NCT06951854
- Testing
- Drug: NV01-A02
- Where
- South Korea
- Volunteers
- 105 people
- Sponsor
- Neuroventi Inc.
Autistic Disorder
A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder
This single center, double-blinded, randomized, placebo-controlled crossover trial will assess the efficacy and safety of extraction of cannabis flowers dissolved in olive oil (30% CBD and 1.5% Δ9-THC) vs.
- Trial name
- NCT05413187
- Testing
- Medical Grade Cannabis oil
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- TO Pharmaceuticals
Autism Spectrum Disorder (ASD)
A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)
This study will investigate the efficacy, safety, tolerability, and pharmacokinetics of RO7017773 in participants aged 15-45 years who have been diagnosed with ASD with a score of >/=50 on the Wechsler Abreviated Scale of…
- Trial name
- NCT04299464
- Testing
- RO7017773
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 104 people
- Sponsor
- Hoffmann-La Roche
Schizophrenia, Bipolar I Disorder
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder
The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia, bipolar I disorder, or autism spectrum disorder (ASD) and to establish…
- Conditions
- Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
- Trial name
- 3070 Ped OLE (NCT04578756)
- Testing
- Cariprazine Flexible Dose
- Where
- 42 sites in United States, Puerto Rico
- Volunteers
- 310 people
- Sponsor
- AbbVie
Autistic Disorder
Study of Fluoxetine in Autism
The purpose of this study is to assess the effect of fluoxetine orally dissolving tablets (ODT) on the repetitive behaviors core domain in children and adolescents with Autistic Disorder.
- Trial name
- SOFIA (NCT00515320)
- Testing
- Fluoxetine
- Where
- 17 sites in United States
- Volunteers
- 158 people
- Sponsor
- Neuropharm
Schizophrenia, Bipolar Disorder
A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children
The purpose of this study is to evaluate the effects of risperidone compared with other atypical antipsychotic drugs on the physical maturity, growth and development of children, and the risk of prolactin-related adverse events…
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Trial name
- NCT01050582
- Testing
- Risperidone, Other atypical antipsychotic drugs
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 244 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Autism, Autistic Disorder
An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
If autism is the consequence of a chronic inflammatory process preventing the infant brain from forming the proper neural connections, then treatment that reduces inflammation might have a positive impact on autism.
- Conditions
- Autism, Autistic Disorder, Asperger's Disorder, PDD
- Trial name
- NCT02199925
- Testing
- Gammaplex 5%
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Isaac Melamed
Autism
Better Social, Emotional Communication, Healthy Relationship and ASD Accommodation Skills: Emotional Intelligence ("EQ") Training for Autistic People and ASD Accommodation Training for People Who Care
Subjects are enrolled in pairs. Pairs consist of an autistic adult age 18-36 and a non-autistic learning partner who has a relationship with the autistic adult, such as a parent.
- Trial name
- NCT07315867
- Testing
- Kairon leadership training for the autistic adult and Kairon autism accommodation training for the learning partner
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Kairon Connect, PBC
Autism Spectrum Disorder, Autism
A 12-Week Crossover Study to Assess the Efficacy, Safety and Tolerability of L1-79 in Subjects Aged 12-21 Years With Autism Spectrum Disorder
This study will investigate the efficacy, safety and tolerability of L1-79 in participants aged 12-21 years who have been diagnosed with ASD with a score of >/= 70 on the Wechsler Abbreviated Scale of Intelligence (WASI-II), and…
- Trial name
- NCT05067582
- Testing
- L1-79
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Yamo Pharmaceuticals LLC
Autistic Disorder, Autism
Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD
Mental Imagery Therapy for Autism (MITA) is a unique, early-intervention application for children with Autism Spectrum Disorder (ASD).
- Conditions
- Autistic Disorder, Autism, ASD
- Trial name
- NCT02708290
- Testing
- MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time
- Where
- United States
- Volunteers
- 6,454 people
- Sponsor
- ImagiRation, LLC